Rating Rationale
October 29, 2020 | Mumbai
Aarti Industries Limited
Long-term rating upgraded to 'CRISIL AA/Stable'; short-term rating reaffirmed ; NCD Withdrawn
 
Rating Action
Total Bank Loan Facilities Rated Rs.1900 Crore
Long Term Rating CRISIL AA/Stable (Upgraded from 'CRISIL AA-/Positive')
Short Term Rating CRISIL A1+ (Reaffirmed)
 
Rs.100 Crore Long-Term Borrowing Programme CRISIL AA/Stable (Upgraded from 'CRISIL AA-/Positive')
Rs.80 Crore Non Convertible Debentures CRISIL AA/Stable (Upgraded from 'CRISIL AA-/Positive' and Withdrawn)
Rs.400 Crore Commercial Paper CRISIL A1+ (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has upgraded its rating on the long term bank facilities and long term borrowing programme of Aarti Industries Limited (AIL) to 'CRISIL AA/Stable' from 'CRISIL AA-/Positive', while reaffirming its rating on short term bank facilities and commercial paper at 'CRISIL A1+'. CRISIL has also withdrawn its rating on Rs 80 crore on the non-convertible debenture of AIL (See Annexure 'Details of Rating Withdrawn' for details) as it is fully redeemed. The rating is withdrawn in line with CRISIL's policy.

The rating action reflects expectation of improvement in the Aarti group's business profile due to continued healthy performance being registered mainly by AIL, supported by its diversified product profile, leading market position in specialty chemicals, and pharmaceuticals segment. The sizeable capex of Rs.2500 crore undertaken in past 3 fiscals, and planned capex of over Rs.2000 crore in fiscals 2021 and 2022, will help bolster production capacities, and help improve revenues as over the medium term. AIL is expected to maintain healthy double digit revenue growth over the medium term, with operating profitability of 19-20%, supported by superior operating capabilities, improving product mix, and better integration of operations, also enabling it to generate healthy cash flows through business cycles.. The company's cash accruals are expected to improve materially over the medium term, from current levels of around Rs.600 crores.

Besides, the group's healthy financial risk profile continues to improve, strengthened by strong cash accruals and equity raising at AIL in fiscal 2019, which helped fund sizeable capital spend and enabled debt protection metrics to improve to comfortable levels.

In spite of COVID-19 impact on the global economy in the first quarter of fiscal 2021, the group posted healthy revenues of Rs 937 crore, 10% lower year-on-year (y-o-y) while operating margin stood at 19.6%. Strong demand from less cyclical end user industries such as pharmaceuticals, agrochemicals and fast moving consumer goods (FMCG) which contribute ~60% to overall revenues, limited decline in revenues. With steady demand, the company is expected to report flattish revenues in fiscal 2021, making up for a slightly weak first quarter. Earlier in fiscal 2020, AIL posted revenues of Rs 4186 crore with operating margin of 23.3%.

Earlier this fiscal, while a 10 year contract (projected revenues of Rs.4000 crore) was terminated, the guarding provisions under the contract providing for appropriate compensation (as per the contract terms) have come into effect. Besides, the company is looking at alternate use of the capacity. Overall with improved cash accruals and cash inflow of Rs.600 crore from contract termination in fiscal 2022, financial risk profile will continue to benefit. The company's gearing, which improved to 0.68 times at March 31, 2020 from 1.26 times in fiscal 2018, supported by Rs.750 crore qualified institutional placement (QIP) issue in March 2019, as well as healthy cash generation, is expected to remain within 0.7-0.9 times over the medium term. Other debt metrics too are expected to remain at comfortable levels.

The ratings continue to reflect AIL's established market position, diversified revenue profile, and sound operating efficiency, supported by a high level of integration as well as healthy and improving financial profile. These strengths are partially offset by large working capital requirement and risks related to implementation of projects and volatility in raw material prices.

Analytical Approach

For arriving at the ratings, CRISIL has combined the business and financial risk profiles of AIL and its subsidiaries, Aarti Corporate Services Ltd, Alchemie (Europe) Ltd, Innovative Envirocare Jhagadia Ltd, Aarti USA Inc., Shanti Intermediaries Pvt Ltd (subsidiary of Aarti Corporate Services Ltd), Nascent Chemical Industries Ltd (subsidiary of Aarti Corporate Services Ltd), Ganesh Polychem Ltd, Aarti Polychem Pvt Ltd, Aarti Organics Limited, Aarti Bharuch Limited, Aarti Pharmachem Limited and Aarti Spechem Limited. This is because all the companies have significant managerial, operational, and financial linkages and collectively are referred to as the Aarti group.

Please refer Annexure - List of entities consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths:
Established market position with diversified revenue, higher revenue visibility and healthy profitability
AIL has maintained its dominant market position in the Nitro chloro benzene (NCB) and D-chloro Benzene (DCB) -based specialty chemicals segment. The group has NCB capacity of 75,000 tonne p.a. (planned to be expanded to 108000 tonnes p.a. over medium term). AIL also has presence in other chemical value chains such as toluene, hydrogenation, ethylation, chlorination, sulphuric acid etc. It has been gradually ramping up capacity utilization of all product lines. Overall the specialty chemical segment contributes to ~80% of revenues and revenues in this segment have grown at compounded annual growth rate (CAGR) of 12% over past four fiscals. AIL is the largest producer of benzene derivatives in India, and a major player among global manufacturers, with a 25-40% global market share across various products. In the pharma segment, contributing ~20% to the overall revenues, the company has diversified presence in active pharma ingredients (APIs), key intermediates as well as Xanthine derivatives. It is the largest manufacturer of xanthine derivatives in India. The pharma segment revenues have registered a CAGR of 15% in the last four fiscals.
 
The group has a diversified revenue profile, reflected in no single customer or product contributing more than 8% to revenue. The group supplies to diverse end-user industries such as polymer additives, pigments, dyes, paints, pharmaceuticals, agrochemicals, fertilizers, and fast-moving consumer goods, and is insulated from downturn in any particular industry. Also, over 40% of its net revenue is from exports, providing geographical diversity. The group has registered healthy revenue growth of 13% in the past 4 fiscals, ending 2020, and barring flattish revenues in fiscal 2021, will continue to maintain double digit profitability growth over the medium term. This is despite termination of one of two large contract manufacturing arrangements entered into with two global multinational companies, which would have provided assured business and high revenue visibility over long term.
 
Sound operating efficiency because of continuous investment in process improvement initiatives and high level of integration
AIL enjoys high economies of scale as it is the largest producer of NCB, DCB,  Nitro Toluene etc. in the domestic market and has built up large and flexible manufacturing capacity. Operating efficiency is also supported by strong research and development (R&D) capability. Integrated operations to manufacture higher order derivatives of benzene, ability to change the product mix according to the demand-supply scenario, and continuous process improvement for maximising the share of value-added benzene derivatives enables AIL to sustain strong operating efficiency. In addition, the group has increased its captive power generation, which will help improve operating efficiency as well as save on power cost. Also in the pharma segment, the group has backward integration in the form of key intermediates for manufacturing of APIs. AIL has significantly low dependence on China for raw materials due to high level of backward integration. With the high level of integration and greater focus on higher margin products, the group has been able to increase the operating margin from 15.3% in fiscal 2014 to 23.3% in fiscal 2020 despite volatility in raw material prices. The return on capital employed (RoCE) has also remained healthy between 15-20% during these fiscals, in spite of large capex. These metrics will continue to remain at healthy levels over the medium term.
 
* Healthy and improving financial risk profile
AIL carried out debt funded capex of about Rs.3600 crore in the past five fiscals, including just over Rs.2500 crore in the last three fiscals. The company also has a capex plan of Rs 2000 crore over fiscal 2021 and 2022 in multiple value chains to increase market share as well as for long term contracts with global MNCs. The additional capex requirements in fiscal 2020 were mainly funded out of proceeds of QIP and internal accrual, leading to lower dependence on external debt. The debt protection metrics as well as gearing levels have improved sharply in the last couple of fiscals. Interest coverage and gearing which were 5.4 times and 1.26 times in fiscal 2018, improved to 7.9 times and 0.68 times in fiscal 2020. Over the medium term, with increase in scale, while borrowings are expected to increase moderately with overall debt remaining around Rs 2300 ' 2400 crore, the debt protection metrics are expected to remain comfortable with interest cover ranging from 7-10 times and gearing remaining below 0.7 times.
 
Weaknesses:
Working capital intensive operations
AIL's operations have remained working capital intensive marked by high gross current assets (GCA) days ranging between 120-150 days in past five years. The higher working capital requirement is mainly owing to requirement to maintain large inventories as the company maintains around two months of raw material inventory and has large number of products in the portfolio leading to high finished goods inventory requirement.
 
* Project risk and risk related to volatility in commodity prices
The company has been carrying out a large capital expansion in past and will continue to do so over medium term, thereby increasing capacities in multiple value chains to increase market share as well as for long term contracts with global MNCs. The company has carried out sizeable capex of Rs.2500 crore in past 3 fiscals, and has planned capex of over Rs.2000 crore in fiscals 2021 and 2022.

Although the capex is in similar product segments, ensuring the projects are completed in stipulated time and within stipulated costs will be critical. Also while the offtake risk is relatively lower due to presence of long term contracts and long term relationships with clients as well as the improved scenario due to supply side reforms in chemical industry in China, overall ramping up of capacities as envisaged, will remain a key monitoring factor.

Additionally, the main raw material, benzene is a crude derivative, prices of which remain susceptible to any sharp volatility in crude prices. While the group has consistently demonstrated its ability to pass on the volatility in raw material prices due to its cost plus business model, which has reflected in consistent operating profitability of 16-23% over last ten fiscals, nevertheless, it remains exposed to the volatility in commodity prices.
Liquidity Strong

AIL has strong liquidity driven by expected cash accruals of over Rs.600 crore per annum (and increasing), and cash and cash equivalents of Rs 220 crore as on August 31, 2020. The utilization of Rs 1200 crore fund based working capital bank limits under consortium (including commercial paper) stood at 80-85% on an average over the eight months ended August 2020. Additionally, the company has unutilised outside consortium limits of ~Rs 500 crore. The group has annual long term repayment obligations of around Rs 280-360 crore over fiscals 2021 to 2023. CRISIL expects internal accruals, cash & cash equivalents and unutilized bank lines to be sufficient to meet the repayment obligations. Besides, the group's capex of ~Rs 2000 crore over fiscal 2021 and 2022, too is expected to be funded mainly from accruals, with low reliance on debt.

Outlook: Stable

CRISIL believes the Aarti group's business risk profile will remain stable over the medium term, backed by healthy market position, good revenue diversity, pick-up in end market demand and strong operating efficiencies. The financial risk profile should also remain healthy driven by improving cash accrual and moderate dependence on debt for capex and working capital funding.

Rating Sensitivity factors
Upward Factors
* Significant and sustained improvement in operating performance leading to increase in cash accruals beyond Rs.850-900 crores.
* Improvement in debt metrics backed by strong cash generation or equity infusion, for instance gearing sustaining below 0.5-0.7 times

Downward Factors
* Material weakening of operating performance, also severely affecting cash accruals below Rs.450 crores.
* Higher than expected debt funded capex or acquisitions, or elongation of working capital cycle, leading to material impact on debt metrics; for instance, gearing increasing above 1.1-1.3 times on sustained basis.
About the Group

AIL, the flagship company of the Aarti group, manufactures organic and inorganic chemicals at its major facilities in Vapi, Jhagadia, Dahej and Kutch, in Gujarat. It also manufactures active pharmaceutical ingredients at its units in Tarapur and Dombivali in Maharashtra, and at Vapi. The company announced demerger of its home & personal care division into separate entity in June 2018. The demerger was completed in June 2019. The group has a strong market position in the nitro-chloro-benzene-based specialty chemicals segment. The company also commissioned greenfield Nitro Toluene facility in Jhagadia, Gujarat in fiscal 2018 and two units for high value specialty chemicals in Dahej in fiscal 2020. In fiscal 2017, it commenced calcium chloride and polydiacetylene (PDA) facilities in Jhagadia, Gujarat and a multipurpose ethylation unit at Dahej, Gujarat. The company also has four full-fledged R&D centres, recognised by the Department of Scientific and Industrial Research, Government of India In fiscal 2020, it commissioned its flagship research and technology centre in Navi Mumbai called the Aarti research and Technology Centre (ARTC) which will house about 250 scientists and engineers.

In first quarter of fiscal 2021, AIL posted operating income of Rs 937 crore and profit after tax of Rs 81 crore as against operating income of Rs 1038 crore and profit after tax of Rs. 142 crore during first quarter of fiscal 2020.

Key Financial Indicators
Particulars Unit 2020 2019
Revenue Rs. Cr. 4186 4168
Profit After Tax (PAT) Rs. Cr. 547 504
PAT Margins % 13.1 12.1
Adjusted Debt/Adjusted Networth Times 0.68 0.89
Interest Coverage Times 7.90 5.30

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments and are included (where applicable) in the Annexure -- Details of Instrument in this Rating Rationale. For more details on the CRISIL complexity levels, please visit www.crisil.com/complexity-levels.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of
Allotment
Coupon
Rate (%)
Maturity date Issue Size
(Rs.Cr)
Compexity level Rating Assigned
with Outlook
NA Commercial Paper NA NA 7-365 days 400 Simple CRISIL A1+
NA Long-Term Borrowing Programme* NA NA NA 100 Simple CRISIL AA/Stable
NA Cash Credit NA NA NA 1200 NA CRISIL AA/Stable
NA Letter Of Credit & Bank Guarantee NA NA NA 600 NA CRISIL A1+
NA Term Loan 31_Mar-2017 8.15% Mar-2024 80 NA CRISIL AA/Stable
NA Term Loan 12-Feb-2014 11% Mar-2021 20 NA CRISIL AA/Stable
*Unallocated
 
Annexure- Details of Rating Withdrawn
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity
date
Issue size (Rs.Crore) Complexity level Rating assigned
INE769A07050 Non-convertible debentures 31-Jul-2014 11.75% Jun-2020 40 Simple Withdrawn
INE769A07068 Non-convertible debentures 31-Jul-2014 11.75% Jun-2021 40 Simple Withdrawn
 
Annexure - List of entities consolidated
Names of Entities Consolidated Extent of Consolidation Rationale for Consolidation
Aarti Corporate Services Ltd Full consolidation All these companies collectively are referred to as the Aarti group and have significant managerial, operational, and financial linkages.
Alchemie Europe Ltd Full consolidation
Innovative Envirocare Jhagadia Ltd Full consolidation
Aarti USA Inc, Full consolidation
Shanti Intermediaries Pvt Ltd Full consolidation
Nascent Chemical Industries Ltd Full consolidation
Ganesh Polychem Ltd Full consolidation
Aarti Polychem Pvt Ltd Full consolidation
Aarti Organics Limited Full consolidation
Aarti Bharuch Limited Full consolidation
Aarti Pharmachem Limited Full consolidation
Aarti Spechem Limited Full consolidation
Annexure - Rating History for last 3 Years
  Current 2020 (History) 2019  2018  2017  Start of 2017
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Commercial Paper  ST  400.00  CRISIL A1+  23-06-20  CRISIL A1+  24-07-19  CRISIL A1+  09-07-18  CRISIL A1+  25-09-17  CRISIL A1+  -- 
        15-01-20  CRISIL A1+  02-04-19  CRISIL A1+  05-01-18  CRISIL A1+       
            06-02-19  CRISIL A1+           
Long-Term Borrowing Programme  LT  100.00
29-10-20 
CRISIL AA/Stable  23-06-20  CRISIL AA-/Positive  24-07-19  CRISIL AA-/Positive  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  CRISIL AA-/Stable 
        15-01-20  CRISIL AA-/Positive  02-04-19  CRISIL AA-/Positive  05-01-18  CRISIL AA-/Stable       
            06-02-19  CRISIL AA-/Stable           
Non Convertible Debentures  LT  0.00
29-10-20 
Withdrawn  23-06-20  CRISIL AA-/Positive  24-07-19  CRISIL AA-/Positive  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  CRISIL AA-/Stable 
        15-01-20  CRISIL AA-/Positive  02-04-19  CRISIL AA-/Positive  05-01-18  CRISIL AA-/Stable       
            06-02-19  CRISIL AA-/Stable           
Fund-based Bank Facilities  LT/ST  1300.00  CRISIL AA/Stable  23-06-20  CRISIL AA-/Positive  24-07-19  CRISIL AA-/Positive  09-07-18  CRISIL AA-/Stable  25-09-17  CRISIL AA-/Stable  CRISIL AA-/Stable 
        15-01-20  CRISIL AA-/Positive  02-04-19  CRISIL AA-/Positive  05-01-18  CRISIL AA-/Stable       
            06-02-19  CRISIL AA-/Stable           
Non Fund-based Bank Facilities  LT/ST  600.00  CRISIL A1+  23-06-20  CRISIL A1+  24-07-19  CRISIL A1+  09-07-18  CRISIL A1+  25-09-17  CRISIL A1+  CRISIL A1+ 
        15-01-20  CRISIL A1+  02-04-19  CRISIL A1+  05-01-18  CRISIL A1+       
            06-02-19  CRISIL A1+           
All amounts are in Rs.Cr.
 
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit 1200 CRISIL AA/Stable Cash Credit 1200 CRISIL AA-/Positive
Letter of credit & Bank Guarantee 600 CRISIL A1+ Letter of credit & Bank Guarantee 600 CRISIL A1+
Term Loan 100 CRISIL AA/Stable Term Loan 100 CRISIL AA-/Positive
Total 1900 -- Total 1900 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for Chemical Industry
CRISILs Criteria for Consolidation

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
B:+91 44 6656 3100
anuj.sethi@crisil.com


Gautam Shahi
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2000
gautam.shahi@crisil.com


Omkar Bibikar
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 3007
Omkar.Bibikar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL